# Acute Heart Failure Diuretic Escalation

Use an early intravenous loop-diuretic response assessment to distinguish underdosing from true resistance, double inadequate doses promptly, then add sequential nephron blockade selectively while monitoring renal function and electrolytes. Reserve ultrafiltration for failure of a stepped pharmacologic strategy.

**Clinical question:** How should intravenous diuretics be titrated and escalated in hospitalized acute heart failure with persistent congestion?

Updated: 2026-09-15T21:56:09.359598+00:00

## What matters in practice
- Start IV loop diuretic therapy promptly in clinically congested acute heart failure; use 20–40 mg IV furosemide in loop-naive patients or at least the chronic oral loop-equivalent dose in patients already receiving loop therapy. [8]
- At 2 hours, urine sodium below 50–70 mEq/L or urine output below 150 mL/hour indicates an inadequate initial response; double the IV loop dose and reassess rather than waiting for next-day weight change. [22][23]
- For persistent congestion despite maximized loop therapy, add a thiazide-type agent first; this improves fluid loss but increases renal dysfunction, hypokalemia, and other electrolyte disturbances. [5][11][19][24]
- Acetazolamide 500 mg once daily added to standardized IV loop therapy improves decongestion, but renal-function monitoring remains necessary. [21][24]
- Do not use routine ultrafiltration as the next escalation step in cardiorenal acute heart failure: stepped pharmacologic therapy preserved renal function better at 96 hours with similar weight loss and fewer serious adverse events. [19][22]

## Start with an adequately dosed intravenous loop diuretic

Apparent diuretic resistance commonly reflects inadequate initial loop-diuretic exposure rather than failure of the drug class.

Use IV loop diuretic therapy for acute heart failure with clinically evident congestion requiring decongestion. For patients not taking a loop diuretic, an initial furosemide dose of 20–40 mg IV is guideline-based. For patients on chronic loop therapy, give at least an IV dose equivalent to the oral home dose; position papers support an initial dose of approximately one to two times the oral home dose. [8]

If congestion is substantial or response to the home-equivalent dose is inadequate, a higher IV loop strategy is reasonable. In DOSE, a high-dose strategy of 2.5 times the oral home dose did not improve the 72-hour global symptom assessment versus a home-dose-equivalent strategy, but it produced greater dyspnea relief, weight loss, and net fluid loss. [8][19]

Administer intermittent IV doses initially and judge effectiveness by early natriuresis or urine output, not by symptom trajectory alone. When a dose achieves the response target, continue that dose every 6–12 hours while congestion persists. Continuous furosemide infusion is an option in refractory cases, but it should not substitute for prompt reassessment after an ineffective bolus. [23]
- Loop-naive patient: furosemide 20–40 mg IV. [8]
- Chronic loop exposure: begin with at least the oral home-dose equivalent administered IV; an initial one- to twofold home-dose approach is used in structured escalation protocols. [8]
- When effective, repeat the established IV dose every 6–12 hours until decongestion. [23]

*Initial IV loop-diuretic dosing and early response assessment in acute heart failure. [8][22][23]*

| Clinical setting | Initial action | Response assessment | Next action |
| --- | --- | --- | --- |
| No chronic loop diuretic | Furosemide 20–40 mg IV. [8] | Check spot urine sodium at 1–2 hours or urine output over the first 2–6 hours. [23] | If urine sodium is below 50–70 mEq/L or urine output is below 150 mL/hour at 2 hours, double the dose. [22][23] |
| Chronic loop diuretic use | Give at least the oral home-dose equivalent IV; a one- to twofold home-dose strategy is used in protocolized care. [8] | Use the same early urine sodium or urine-output targets. [22][23] | If targets are met, repeat every 6–12 hours; if not, double and reassess. [23] |
| Persistent congestion after an effective loop dose | Continue the effective loop dose every 6–12 hours. [23] | Track clinical decongestion and renal function/electrolytes during continued diuresis. [15][16] | Add a second diuretic only after an adequate loop strategy has failed to achieve decongestion. [11][19] |

## Use urine sodium or urine output to identify inadequate natriuresis early

Early response metrics allow same-day escalation before persistent congestion becomes entrenched.

Obtain a spot urine sodium concentration 1–2 hours after the initial IV loop dose when catheterized or reliably collected urine is available. A value below 50–70 mmol/L at 2 hours indicates inadequate natriuresis and should trigger dose escalation. A spot sample has shown strong correlation with total sodium excretion and urine output from a 6-hour collection. [21][22][23]

If spot urine sodium is impractical, use hourly urine output. A target above 150 mL/hour at 2 hours supports adequate response; output below this threshold should prompt doubling of the prior IV loop dose, followed by repeat assessment 2 hours later. [23]

European guidance also recognizes a 6-hour urine-output assessment after IV loop administration. Structured urine sodium-guided approaches increase diuretic intensification and natriuresis, but the role of serial urine sodium testing in improving definitive clinical outcomes remains under evaluation. [9][10][22]
- Spot urine sodium: obtain 1–2 hours after IV loop administration; below 50–70 mmol/L is inadequate response. [21][22][23]
- Urine output alternative: target more than 150 mL/hour; reassess at 2 hours after the initial or escalated dose. [23]
- Do not label resistance after one low dose: repeat with a doubled IV loop dose before adding a second nephron-segment agent. [20][23]

### Interpret a creatinine rise in the context of decongestion

Follow serum creatinine and electrolytes during IV diuretic escalation because loop diuretics and combination therapy can worsen renal function and disturb potassium and sodium balance. A creatinine increase must be interpreted alongside residual congestion and diuretic response rather than used automatically to stop decongestion. [15][16][19]
- Escalate laboratory surveillance when adding a thiazide-type diuretic or acetazolamide because combination regimens increase the risk of renal and electrolyte adverse effects. [5][24]
- Avoid relying on creatinine- or cystatin C-based estimated GFR as a precise real-time measure of filtration during acute heart failure; both may be misleading in this setting. [17]

*Action thresholds for early IV loop-diuretic response. [21][22][23]*

| Metric | Timing after IV loop dose | Adequate response | Inadequate response and action |
| --- | --- | --- | --- |
| Spot urine sodium | 1–2 hours. [21][23] | More than 50–70 mEq/L. [23] | Below 50–70 mEq/L: double the loop-diuretic dose and repeat assessment. [22][23] |
| Urine output | Assess at 2 hours; hourly monitoring may continue through 6 hours. [10][23] | More than 150 mL/hour. [23] | Below 150 mL/hour: double the loop-diuretic dose and reassess after the repeat dose. [23] |
| Persistent congestion despite response targets | During serial daily assessment. | Ongoing urine output does not alone establish complete decongestion. | Continue effective loop dosing and assess for residual congestion before discharge because incomplete decongestion is associated with rehospitalization and mortality. [5][22] |

## Double an ineffective loop dose before declaring diuretic resistance

Dose escalation should be response-guided and repeated promptly until natriuresis or urine-output targets are reached.

When the initial IV loop dose fails to achieve urine sodium above 50–70 mEq/L or urine output above 150 mL/hour at 2 hours, double the prior dose and repeat the same response measurement 2 hours later. Continue this loop-dose escalation until the response target is achieved or the maximum protocol dose is reached. [23]

Once a response is established, maintain the effective dose every 6–12 hours rather than reverting to the ineffective starting dose. In a practical stepped strategy, persistent congestion with urine output below 3–4 L over 24 hours despite high-dose or maximized loop therapy is a trigger to add another diuretic mechanism. [19]

Use the lowest loop dose that produces meaningful decongestion once euvolemia is approaching, because loop treatment requires an ongoing balance between decongestion and renal dysfunction, electrolyte disturbance, and neurohormonal activation. [3][8][19]
- Failure at 2 hours: double the preceding IV loop dose. [23]
- Success at 2 hours: continue the effective dose every 6–12 hours. [23]
- Failure despite maximized loop therapy and urine output below 3–4 L/day with persistent congestion: proceed to adjunctive therapy. [19]

*Stepwise escalation after an inadequate IV loop response. [19][23]*

| Step | Trigger | Action | Reassessment |
| --- | --- | --- | --- |
| 1. Initial loop dose | Clinical congestion requiring IV decongestion. | Use loop-naive or chronic-loop starting strategy. [8] | Spot urine sodium at 1–2 hours or urine output by 2 hours. [23] |
| 2. Loop-dose escalation | Urine sodium below 50–70 mEq/L or urine output below 150 mL/hour. [22][23] | Double the prior IV loop dose. [23] | Repeat urine sodium or output assessment 2 hours later. [23] |
| 3. Sequential blockade | Persistent congestion and inadequate output despite high-dose/maximized loop therapy; practical threshold below 3–4 L urine output in 24 hours. [19] | Add a thiazide-type diuretic first; consider acetazolamide as an alternative add-on. [19][21] | Monitor creatinine and electrolytes closely. [5][15][24] |
| 4. Rescue therapy | Failure of stepped pharmacologic decongestion. | Consider ultrafiltration selectively rather than routinely. [19] | Compare renal trajectory, weight loss, adverse events, and ongoing congestion. [22] |

## Add a second diuretic only after loop optimization fails

Sequential nephron blockade improves short-term fluid removal but shifts risk toward electrolyte depletion and renal dysfunction.

For resistant edema that does not respond to higher loop-diuretic doses, add a thiazide-type diuretic to block distal tubular sodium reabsorption. European guidance gives loop-thiazide combination therapy a class IIa, level B recommendation in this situation. In CLOROTIC, oral hydrochlorothiazide added to IV furosemide improved diuretic response and produced greater 72-hour weight loss than placebo. [11][21]

Use thiazide augmentation with active electrolyte and renal surveillance. Across CLOROTIC analyses, combination treatment increased fluid loss but was associated with more renal-function and electrolyte disturbances; meta-analytic evidence also associates loop-thiazide therapy with worsening renal function and hypokalemia. [5][24]

Do not exclude thiazide augmentation solely because eGFR is below 30 mL/min/1.73 m². The historical assumption of absent efficacy at this threshold has been challenged, and CLOROTIC found no significant interaction between eGFR subgroup and hydrochlorothiazide effects on diuretic response or safety endpoints. [11]
- Preferred first add-on after an optimized loop strategy fails: thiazide-type diuretic. [19][23]
- Hydrochlorothiazide plus IV furosemide improves diuretic response, including in patients with impaired kidney function, but requires monitoring for hypokalemia, hyponatremia, and renal dysfunction. [11][24]
- Evidence does not establish a preferred thiazide-like agent between oral metolazone and IV chlorothiazide in acute heart failure with renal dysfunction. [12]

### Use acetazolamide as an alternative proximal-tubule add-on

Acetazolamide 500 mg once daily added to standardized IV loop diuretics improved decongestion in acute decompensated heart failure with volume overload. It is a reasonable add-on when persistent congestion remains after loop optimization, particularly when a proximal-tubule strategy is preferred over thiazide escalation. [2][21]

Monitor renal function and electrolytes after acetazolamide initiation. Network meta-analysis data associate loop plus acetazolamide with worsening renal function, although thiazide combinations carry a clearer hypokalemia signal. [24]
- Dose supported by ADVOR-related evidence: acetazolamide 500 mg once daily as an add-on to standardized IV loop therapy. [21]
- Expected tradeoff: improved decongestion with potential worsening renal function requiring laboratory monitoring. [21][24]

### Do not use SGLT2 inhibitors as an acute substitute for loop escalation

SGLT2 inhibitors may have favorable renal safety signals and may reduce heart-failure hospitalization in selected diuretic-resistance studies, but the comparative evidence is indirect and imprecise. In acute congestion, use response-guided IV loop optimization first; consider SGLT2 inhibitor therapy in hemodynamically stable patients as part of broader heart-failure treatment rather than as a replacement for immediate natriuretic escalation. [6][19]
- SGLT2 inhibitor evidence in diuretic resistance remains exploratory relative to established loop escalation and sequential nephron blockade. [6]
- Do not delay loop-dose escalation while awaiting the slower clinical effects of a disease-modifying therapy. [19][23]

*Adjunctive strategies for persistent congestion after optimized IV loop therapy. [5][6][11][19][21][24]*

| Strategy | When to use | Expected benefit | Major tradeoff |
| --- | --- | --- | --- |
| Thiazide-type diuretic plus loop | Resistant edema after failure to respond to increased loop dose. [11] | Greater diuretic response and fluid loss; hydrochlorothiazide improved 72-hour weight loss in CLOROTIC. [11][21] | Higher risk of renal-function and electrolyte disturbances, including hypokalemia. [5][24] |
| Acetazolamide 500 mg once daily plus loop | Persistent volume overload after loop optimization when an alternative add-on strategy is selected. [21] | Improved decongestion with standardized IV loop therapy. [21] | Worsening renal function signal; monitor kidney function and electrolytes. [24] |
| SGLT2 inhibitor plus loop | Selected stable patients; not as immediate rescue for an inadequate initial loop response. [6] | Potential reduction in rehospitalization with favorable renal signal in selected trials. [6] | Indirect comparisons and wide confidence intervals limit certainty for acute resistance treatment. [6] |

## Reserve ultrafiltration for pharmacologic failure and discharge only after decongestion

Mechanical fluid removal is a rescue option, not a routine substitute for a structured diuretic escalation strategy.

Consider ultrafiltration only when adequate loop dosing and adjunctive pharmacologic strategies fail to achieve decongestion. In CARRESS-HF, a stepped pharmacologic algorithm was superior to ultrafiltration for preservation of renal function at 96 hours, with similar weight loss. [19][20]

In the CARRESS-HF comparison, serum creatinine increased by 0.23 mg/dL with ultrafiltration versus decreased by 0.04 mg/dL with stepped pharmacologic therapy at 96 hours; weight loss was similar, and serious adverse events through 60 days were more frequent with ultrafiltration (72% versus 57%). These findings favor continued pharmacologic escalation in patients who remain candidates for it. [22]

Before discharge, confirm that congestion has been meaningfully resolved rather than accepting symptomatic improvement alone. Residual congestion at discharge is associated with higher heart-failure readmission and mortality, making completion of decongestion a central inpatient target. [5][22]
- Ultrafiltration indication: persistent congestion after failure of stepped pharmacologic decongestion. [19]
- In cardiorenal acute heart failure, favor stepped pharmacologic treatment over routine ultrafiltration to preserve renal function at 96 hours. [19][22]
- Discharge priority: avoid residual congestion, which is associated with subsequent rehospitalization and death. [5][22]

*Ultrafiltration versus stepped pharmacologic therapy in CARRESS-HF. [22]*

| Outcome | Ultrafiltration | Stepped pharmacologic therapy | Clinical implication |
| --- | --- | --- | --- |
| Change in serum creatinine at 96 hours | +0.23 ± 0.70 mg/dL. [22] | −0.04 ± 0.53 mg/dL. [22] | Stepped pharmacologic therapy better preserved renal function. [22] |
| Weight loss at 96 hours | 5.7 ± 3.9 kg. [22] | 5.5 ± 5.1 kg. [22] | No meaningful weight-loss advantage for ultrafiltration. [22] |
| Serious adverse events through 60 days | 72%. [22] | 57%. [22] | Use ultrafiltration selectively after pharmacologic failure. [22] |

## References
1. Vascular (dys)function in the failing heart | Nature Reviews Cardiology — www.nature.com — https://www.nature.com/articles/s41569-025-01163-w
2. Efficacy of combining acetazolamide with loop diuretics versus double dose loop diuretics for decongestion in patients with chronic kidney disease: a randomized controlled trial | Scientific Reports — www.nature.com — https://www.nature.com/articles/s41598-026-50753-2
3. Loop Diuretic Applications in Heart Failure Management | Cardiology | Cardiovascular Medicine and Haematology | Health sciences | Topics | Nature Index — www.nature.com — https://www.nature.com/nature-index/topics/l4/loop-diuretic-applications-in-heart-failure-management
4. Guideline-directed medical strategies for the co-management of ... — www.nature.com — https://www.nature.com/articles/s43856-025-00951-2
5. Simplifying Treatment of Congestion: Diuretic Response With Sequential Nephron Blockade Is Independent of Ejection Fraction — www.jacc.org — https://www.jacc.org/doi/10.1016/j.jchf.2024.05.024
6. Comparative Strategies to Overcome Diuretic Resistance in Heart Failure: A Network Meta-Analysis — www.jacc.org — https://www.jacc.org/doi/10.1016/j.jacadv.2026.102617
7. Simplifying Treatment of Congestion: Diuretic Response With Sequential Nephron Blockade Is Independent of Ejection Fraction | JACC: Heart Failure — www.jacc.org — https://www.jacc.org/doi/abs/10.1016/j.jchf.2024.05.024
8. Rationale and Design of the Efficacy of a Standardized Diuretic Protocol in Acute Heart Failure Study - Dauw - 2021 - ESC Heart Failure - Wiley Online Library — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/full/10.1002/ehf2.13666
9. Rationale and Design of the DECONGEST (Diuretic Treatment in Acute Heart Failure With Volume Overload Guided by Serial Spot Urine Sodium Assessment) Study - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S1071916424003609
10. Diuretic resistance measured by sodium excretion and urine output in acute heart failure: The DIURESIS-AHF study - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0914508725001716
11. Combining loop and thiazide diuretics for acute heart failure across the estimated glomerular filtration rate spectrum: A post‐hoc analysis of the CLOROTIC trial - Trullàs - 2023 - European Journal of Heart Failure - Wiley Online Library — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/full/10.1002/ejhf.2988
12. Metolazone Versus Chlorothiazide as Add-On Therapy to Loop Diuretics in Patients with Acute Decompensated Heart Failure and Renal Insufficiency - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S1071916413004570
13. Practical Outpatient Management of Worsening Chronic Heart Failure — academic.oup.com — https://academic.oup.com/eurjhf/article/24/5/750/8364290
14. Diuretic - an overview | ScienceDirect Topics — www.sciencedirect.com — https://www.sciencedirect.com/topics/veterinary-science-and-veterinary-medicine/diuretic
15. Advanced chronic kidney disease coexisting with heart failure — academic.oup.com — https://academic.oup.com/ckj/article/18/5/sfaf128/8124383
16. Renal function, electrolytes, and congestion monitoring in heart failure — academic.oup.com — https://academic.oup.com/eurheartjsupp/article/21/Supplement_M/M25/5691317
17. KDIGO 2024 Clinical Practice Guideline for the Evaluation and ... — www.kidney-international.org — https://www.kidney-international.org/article/%20S0085-2538%2823%2900766-4/fulltext
18. Diuretics in critically ill patients: a narrative review of their ... — www.bjanaesthesia.org — https://www.bjanaesthesia.org/article/S0007-0912(25)00159-X/fulltext
19. Diuretic Treatment in Heart Failure: A Practical Guide for Clinicians — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC11313642
20. Systematic Review on the Management of Diuretic Resistance in Acute Heart Failure across the Spectrum of Kidney Disease — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC12215157
21. Kidney Disease and Heart Failure: Recent Advances and Current Challenges — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC13092174
22. From Hospital to Home — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC11342447
23. [PDF] How do we maximize diuresis in acute decompensated heart failure? — www.ccjm.org — https://www.ccjm.org/content/ccjom/89/10/561.full-text.pdf
24. ESC 365 - Diuretic strategies in acute heart failure: a systematic review and network meta-analysis of randomized clinical trials — esc365.escardio.org — https://esc365.escardio.org/journal/90306

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.